Immunolocalization of interleukin-1 receptor antagonist in healthy and infarcted myocardium

Histology and Histopathology

Volumn 23, Issue 9, 2008, Pages 1093-1102

  Bonetti, A ^a   Marchini, M ^a   Ortolani, F ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Cardiomyocyte; Heart; IL 1ra; Interleukin 1 receptor antagonist; Myocardium infarction

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; EXTRACELLULAR MATRIX; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; ULTRASTRUCTURE;

BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, INTERLEUKIN-1;

EID: 84863982298     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Abe S., Okura Y., Hoyano M., Kazama R., Watanabe S., Ozawa T., Saigawa T., Hayashi M., Yoshida T., Tachikawa H., Kashimura T., Suzuki K., Nagahashi M., Watanabe J., Shimada K., Hasegawa G., Kato K., Hanawa H., Kodama M. and Aizawa Y. (2004). Plasma concentrations of cytokines and neurohumoral factors in a case of fulminant myocarditis successfully treated with intravenous immunoglobulin and percutaneous cardiopulmonary support. Circ. J. 68, 1223-1226.
2. Akasaka Y., Morimoto N., Ishikawa Y., Fujita K., Ito K., Kimura-Matsumoto M., Ishiguro S., Morita H., Kobayashi Y. and Ishii T. (2006). Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod. Pathol. 19, 588-598.
3. Allan S.M. (1998). The role of pro- and antiinflammatory cytokines in neurodegeneration. Ann. NY Acad. Sci. 866, 84-93.
4. Arend W.P. (2002). The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13, 323-340.
5. Arend W.P. and Gabay C. (2000). Physiologic role of interleukin-1 receptor antagonist. Arthritis Res. 2, 245-248.
6. Arend W.P. and Guthridge C.J. (2000). Biological role of interleukin 1 receptor antagonist isoforms. Ann. Rheum. Dis. 59 (suppl. I), i60-i64.
7. Arend W.P., Joslin F.G. and Massoni R.J. (1985). Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 134, 3868-3875.
8. Arend W.P., Malyak M., Guthridge C.J. and Gabay C. (1998). Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16, 27-55.
9. Balbay Y., Tikiz H., Baptiste R.J., Ayaz S., Sasmaz H. and Korkmaz S. (2001). Circulating IL-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction. Angiology 52, 109-114.
10. Casini-Raggi V., Kam L., Chong Y.J.T., Fiocchi C., Pizarro T.T. and Cominelli F. (1995). Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154, 2434-2440.
11. Chimenti S., Carlo E., Masson S., Bai A. and Latini R. (2004). Myocardial infarction: animal models. Methods Mol. Med. 98, 217-226.
12. Daig R., Rogler G., Aschenbrenner E., Vogl D., Falk W., Gross V., Scholmerich J. and Andus T. (2000). Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 46, 350-358.
13. Danowski B.A., Imanaka-Yoshida K., Sanger J.M. and Sanger J.W. (1992). Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. J. Cell Biol. 118, 1411-1420.
14. Dewberry R., Holden H., Crossman D. and Francis S. (2000). Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 2394-2400.
15. di Febbo C., Baccante G., Reale M., Castellani M.L., Angelini A., Cuccurullo F. and Porreca E. (1998). Transforming growth factor beta1 induces IL-1 receptor antagonist production and gene expression in rat vascular smooth muscle cells. Atherosclerosis 136, 377-382.
16. Firestein G.S., Berger A.E., Tracey D.E., Chosay J.G., Chapman D.L., Paine M.M., Yu C. and Zvaifler N.J. (1992). IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J. Immunol. 149, 1054-1062.
17. Francis S.E., Holden H., Holt C.M. and Duff G.W. (1998). Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J. Mol. Cell. Cardiol. 30, 215-223.
18. Gabay C., Smith M.F. jr, Eidlen D. and Arend W.P. (1997). IL-1 receptor antagonist is an acute-phase protein. J. Clin. Invest. 99, 2930-2940.
19. Galea J., Armstrong J., Gadson P., Holden H., Francis S.E. and Holt C.M. (1996). Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16, 1000-1006.
20. Guillen I., Blanes M., Gomez-Lechon M.J. and Castell J.V. (1995). Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am. J. Physiol. 269, R229-R235.
21. Hagaman D.D., Okayama Y., D'Ambrosio C., Prussin C., Gilfillan A.M. and Metcalfe D.D. (2001). Secretion of interleukin-1 receptor antagonist from human mast cells after immunoglobulin E-mediated activation and after segmental antigen challenge. Am. J. Respir. Cell. Mol. Biol. 25, 685-691.
22. Haskill S., Martin G., Van Le L., Morris J., Peace A., Bigler C.F., Jaffe G.J., Hammerberg C., Sporn S.A. and Fong S. (1991). cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc. Natl. Acad. Sci. USA 88, 3681-3685.
23. Latini R., Bianchi M., Correale E., Dinarello C.A., Fantuzzi G., Frasco C., Maggioni A.P., Mengozzi M., Romano S. and Shapiro L. (1994). Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J. Cardiovasc. Pharmacol. 23, 1-6.
24. Loddick S.A., Wong M.L., Bongiorno P.B., Gold P.W., Licinio J., Rothwell N.J. (1997). Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem. Biophys. Res. Commun. 234, 211-215.
25. Loppnow H., Westphal E., Buchhorn R., Wessel A. and Werdan K. (2001). Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock 16 (suppl. I), 3-9.
26. Malyak M., Guthridge J.M., Hance K.R., Dower S.K., Freed J.H. and Arend W.P. (1998). Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J. Immunol. 161, 1997-2003.
27. Maron B.J. and Ferrans V.J. (1978). Ultrastructural features of hypertrophied human ventricular myocardium. Prog. Cardiovasc. Dis. 21, 207-238.
28. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. (1994). Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 72, 561-566.
29. Mayer J., Rau B., Gansauge F. and Beger H.G. (2000). Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 47, 546-552.
30. Mikuniya T., Nagai S., Takeuchi M. and Izumi T. (2000). Significance of the interleukin-1 receptor antagonist/interleukin-1b ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration 67, 389-396.
31. Missov E., Campbell A. and Lebel B. (1997). Cytokine inhibitors in patients with heart failure and impaired functional capacy. Jpn. Circ. J. 61, 749-754.
32. Müller-Werdan U., Schumann H., Loppnow H., Fuchs R., Darmer D., Stadler J., Holtz J. and Werdan K. (1998). Endotoxin and tumor necrosis factor-alpha exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J. Mol. Cell. Cardiol. 30, 1027-1036.
33. Muzio M., Polentarutti N., Sironi M., Poli G., De Gioia L., Introna M., Mantovani A. and Colotta F. (1995). Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J. Exp. Med. 82, 623-628.
34. Najjam S., Gibbs R.V., Gordon M.Y. and Rider C.C. (1997). Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach. Cytokine 9, 1013-1022.
35. Oyama J., Shimokawa H., Morita S., Yasui H. and Takeshita A. (2001). Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. Coron. Artery Dis. 12, 567-571.
36. Patti G., D'Ambrosio A., Mega S., Giorni G., Zardi E.M., Zardi D.M., Dicuonzo G., Dobrina A. and Di Sciascio G. (2004). Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 43, 35-38.
37. Pereira B.J.G., Shapiro L., King A.J., Falagas M.E., Strom J.A. and Dinarello C.A. (1994). Plasma levels of IL-1ß, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 45, 890-896.
38. Pomerantz B.J., Reznikov L.L., Harken A.H. and Dinarello C.A. (2001). Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1 beta. Proc. Natl. Acad. Sci. USA 98, 2871-2876.
39. Samarel A.M. (2005). Costameres, focal adhesions, and cardiomyocyte mechanotransduction. Am. J. Physiol. Heart Circ. Physiol. 289, H2291-H2301.
40. Saraste A., Pulkki K., Kallajoki M., Henriksen K., Parvinen M., Voipio- Pullki L.M. (1997). Apoptosis in human acute myocardial infarction. Circulation 95, 320-323.
41. Sekiyama K.D., Yoshiba M. and Thomson A.W. (1994). Circulating proinflammatory cytokines (IL-1ß, TNF-α, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin. Exp. Immunol. 98, 71-77.
42. Shibata M., Endo S., Inada K., Kuriki S., Harada M., Takino T., Sato N., Arakawa N., Suzuki T., Aoki H., Suzuki T. and Hiramori K. (1997). Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. J. Interferon Cytokine Res. 17, 145-150.
43. Suzuki K., Murtuza B., Smolenski R.T., Sammut I.A., Suzuki N., Kaneda Y. and Yacoub M.H. (2001). Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104 (suppl. I), I308-I313.
44. Tam F.W.K., Smith J., Cashman S.J., Wang Y., Thompson E.M. and Rees A.J. (1994). Glomerular expression of interleukin-1 receptor antagonist and interleukin-1ß genes in antibody-mediated glomerulonephritis. J. Clin. Invest. 145, 126-136.
45. Tipping P.G. and Hancock W.W. (1993). Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am. J. Pathol. 142, 1721-1728.
46. Ukimura A., Terasaki F., Fujioka S., Deguchi H., Kitaura Y., Isomura T. and Suma H. (2003). Quantitative analysis of cytokine mRNA expression in hearts from patients with nonischemic dilated cardiomyopathy (DCM). J. Card. Surg. 18 (suppl. 2), S101-S108.
47. Vary T.C., Owens E.L., Beers J.K., Verner K. and Cooney R.N. (1996). Sepsis inhibits synthesis of myofibrillar and sarcoplasmic proteins: modulation by interleukin-1 receptor antagonist. Shock 6, 13-8.
48. Wong M.L., Bongiorno P.B., Rettori V., McCann S.M. and Licinio J. (1997). Interleukin (IL) 1b, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc. Natl. Acad. Sci. USA 94, 227-232.
49. Yaoita H., Ogawa K., Maehara K. and Maruyama Y. (1998). Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 97, 276-281.
50. Yaoita H., Ogawa K., Maehara K. and Maruyama Y. (2000). Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction. Cardiovasc. Res. 45, 630-641.
51. Zamir O., O'Brien W., Thompson R., Bloedow D.C., Fischer J.E. and Hasselgren P.O. (1994). Reduced muscle protein breakdown in septic rats following treatment with interleukin-1 receptor antagonist. Int. J. Biochem. 26, 943-950.